Skip to main content
. 2015 Aug 7;24(21):6093–6105. doi: 10.1093/hmg/ddv321

Figure 5.

Figure 5.

Anti-Aß scFvs protect neuronal architecture in the brain. (A and B) Expression of transgenes in the mushroom bodies with OK107-Gal4; UAS-CD8-GFP followed by GFP imaging. (A) Three-dimensional architecture of the mushroom body complex at Day 1 in flies of the indicated genotypes. Compared with LacZ, expression of Aß42 reduces the size of the axonal terminals of the mushroom bodies (arrow). Co-expression of scFv9 does not rescue Aß42 (arrow), but co-expression of scFv42.2 rescues partially (arrow). The combination of both anti-Aß scFvs completely rescues the size of the mushroom body lobes at Day 1 (arrow). (B) Single-plane images of calyces from flies of the indicated genotypes at Days 1, 20, 30 and 40. Day 1: compared with control LacZ, co-expression of Aß42 and LacZ results in slightly larger calyces. Co-expression of scFvs also induces slightly larger calycal sizes at Day 1. Day 20: flies co-expressing Aß42 and LacZ exhibit smaller calyces than LacZ controls. Co-expression of Aß42 and either scFv9 or scFv42.2 preserves the size of the calyces. Co-expression of both anti-Aß scFvs results in larger calyces. Day 40: co-expression of Aß42 and LacZ results in very small calyces that are not rescued by scFv9. Co-expression of Aß42 and scFv42.2 results in partial improvement in the volume of the calyces, similar to co-expression of both scFvs. (C) Quantification of the axonal surface at Day 1. (D) Quantification of calycal volume at three time points. Values are shown as averages and standard deviation of the media. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.